Human Anti-HIV-1 gp120 Recombinant Antibody (clone KD-247)

Figure 1 The gp120 mutation profile of HIV-1BaL evasion variants from KD-247 in vitro.

The ratio of the PNGS insertion in the V2 region and mutations in the C2 and V3 regions in gp120 of HIV-1BaL variants were plotted for each passage. The y-axis indicates the percentage of PNGS insertions or mutations in the tested clones and the x-axis shows the concentration of KD-247 (μg/ml).

Hatada, M., Yoshimura, K., Harada, S., Kawanami, Y., Shibata, J., & Matsushita, S. (2010). Human immunodeficiency virus type 1 evasion of a neutralizing anti-V3 antibody involves acquisition of a potential glycosylation site in V2. Journal of General Virology, 91(5), 1335-1345.

Figure 2 Sensitivities of HIV-1 strains pseudo-typed with recombinant HIV-1BaLenv genes to KD-247 inhibitor.

KD-247 was pre-incubated with 300 TCID50 of each HIV-1BaL pseudotype virus for 30 min, then added to TZM-bl target cells. Inhibitory effects were determined by measuring β-galactosidase activity on day 2 of culture.

Hatada, M., Yoshimura, K., Harada, S., Kawanami, Y., Shibata, J., & Matsushita, S. (2010). Human immunodeficiency virus type 1 evasion of a neutralizing anti-V3 antibody involves acquisition of a potential glycosylation site in V2. Journal of General Virology, 91(5), 1335-1345.